Veraxa Biotech Holding AG (NASDAQ:VRXA – Get Free Report) was the recipient of a large decline in short interest in the month of August. As of August 31st, there was short interest totaling 202,960 shares, a decline of 46.3% from the August 15th total of 378,219 shares. Currently, 0.6% of the shares of the company are short sold. Based on an average daily volume of 204,024 shares, the short-interest ratio is presently 1.0 days.
Veraxa Biotech Stock Down 0.7%
Shares of NASDAQ VRXA opened at $1.51 on Thursday. Veraxa Biotech has a 52 week low of $1.27 and a 52 week high of $27.36.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded shares of Veraxa Biotech from a “sell” rating to a “hold” rating in a research report on Monday, August 31st.
Insider Transactions at Veraxa Biotech
In other Veraxa Biotech news, Director Oliver Rolf Baumann bought 50,000 shares of the firm’s stock in a transaction on Thursday, August 27th. The shares were purchased at an average price of $1.50 per share, for a total transaction of $75,000.00. Following the transaction, the director directly owned 5,773,618 shares in the company, valued at approximately $8,660,427. This trade represents a 0.87% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Veraxa Biotech Company Profile
Veraxa Biotech AG is a biotechnology company focused on developing targeted therapies for cancer and other serious diseases. Its research is centered on antibody-drug conjugates and related drug-conjugate technologies designed to deliver potent therapeutic agents selectively to diseased cells.
The company’s approach combines tumor-targeting antibodies with drug payloads, with the goal of improving treatment precision while limiting exposure to healthy tissue. Veraxa’s development activities include advancing its proprietary technology platforms and evaluating potential therapeutic candidates through preclinical and clinical research.
Veraxa Biotech is headquartered in Germany and operates in the biopharmaceutical sector.
See Also
- Five stocks we like better than Veraxa Biotech
- This Gold ETF Turns a Non-Yielding Asset Into Monthly Income—But There’s a Catch
- Analysts See Double-Digit Upside for These 3 Stocks
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
Receive News & Ratings for Veraxa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veraxa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
